Menu Search
Equities

Noile-Immune Biotech Inc

4893:TYO

Noile-Immune Biotech Inc

Actions
  • Price (JPY)172.00
  • Today's Change4.00 / 2.38%
  • Shares traded640.70k
  • 1 Year change-56.78%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 06:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Noile-Immune Biotech Inc's revenues fell -49.37% from 625.78m to 316.82m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 386.62m to a larger loss of 1.13bn.
Gross margin95.58%
Net profit margin-13,139.53%
Operating margin-14,436.06%
Return on assets-19.15%
Return on equity-19.63%
Return on investment-19.61%
More ▼

Cash flow in JPYView more

In 2023, Noile-Immune Biotech Inc increased its cash reserves by 22.89%, or 1.03bn. Cash Flow from Financing totalled 1.91bn or 603.84% of revenues. In addition the company used 873.08m for operations while cash used for investing totalled 5.32m.
Cash flow per share-14.39
Price/Cash flow per share--
Book value per share113.23
Tangible book value per share113.23
More ▼

Balance sheet in JPYView more

Noile-Immune Biotech Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 5.56bn.
Current ratio79.74
Quick ratio79.60
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.